Results 141 to 150 of about 53,405 (189)
Some of the next articles are maybe not open access.
Clinical Journal of Oncology Nursing, 2002
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and ...
Kathy Wilkinson, Monica P. Davey
+12 more sources
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and ...
Kathy Wilkinson, Monica P. Davey
+12 more sources
Interaction of imatinib mesylate with human serum transferrin: The comparative spectroscopic studies
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017Urszula Śliwińska-Hill
exaly +2 more sources
AAPS PharmSciTech, 2021
Neurodegenerative diseases like Alzheimer’s disease require treatment where it is essential for drug to reach brain. Nose to brain delivery of drugs enables direct transport to brain bypassing blood brain barrier. Imatinib mesylate, an anti-cancer agent,
Raju Saka, Naveen Chella, Wahid Khan
semanticscholar +1 more source
Neurodegenerative diseases like Alzheimer’s disease require treatment where it is essential for drug to reach brain. Nose to brain delivery of drugs enables direct transport to brain bypassing blood brain barrier. Imatinib mesylate, an anti-cancer agent,
Raju Saka, Naveen Chella, Wahid Khan
semanticscholar +1 more source
, 2020
Herein, we describe an electrochemical, economically viable, rapid, and optimized procedure to synthesize of sphere Al2W3O12 nanoparticles of 40 nm mean particle size.
Somayeh Mirsadeghi +8 more
semanticscholar +1 more source
Herein, we describe an electrochemical, economically viable, rapid, and optimized procedure to synthesize of sphere Al2W3O12 nanoparticles of 40 nm mean particle size.
Somayeh Mirsadeghi +8 more
semanticscholar +1 more source
In Analysis, 2019
Fe3O4 nanoparticles with chitosan grafted onto poly(N-vinylcaprolactam) copolymers are synthesized and showed dual sensitivity to temperature and pH. The nanoparticles were characterized by different techniques and two aspects of their applications were ...
H. Sahebi +3 more
semanticscholar +1 more source
Fe3O4 nanoparticles with chitosan grafted onto poly(N-vinylcaprolactam) copolymers are synthesized and showed dual sensitivity to temperature and pH. The nanoparticles were characterized by different techniques and two aspects of their applications were ...
H. Sahebi +3 more
semanticscholar +1 more source
Journal of Separation Science, 2019
The efficiency of a molecularly imprinted polymer as a selective packing material for solid-phase extraction of imatinib mesylate sorption was investigated.
Atefeh Kazemi +2 more
semanticscholar +1 more source
The efficiency of a molecularly imprinted polymer as a selective packing material for solid-phase extraction of imatinib mesylate sorption was investigated.
Atefeh Kazemi +2 more
semanticscholar +1 more source
2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
Journal of Chemical and Engineering Data, 2018
The solubility of imatinib mesylate in nine monosolvents and two binary solvents was determined by the shaken flask method followed by UV composition analysis from 278.15 to 318.15 K at atmospheric pressure.
Xinyi Wang +5 more
semanticscholar +1 more source
The solubility of imatinib mesylate in nine monosolvents and two binary solvents was determined by the shaken flask method followed by UV composition analysis from 278.15 to 318.15 K at atmospheric pressure.
Xinyi Wang +5 more
semanticscholar +1 more source
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2006Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Strebhardt, K., Ullrich, A.
openaire +3 more sources
An evaluation of the cardiotoxicity of imatinib mesylate
Leukemia Research, 2008We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and ...
Antonio Luiz, Ribeiro +6 more
openaire +2 more sources